Benitec Biopharma, Inc. (BNTC)
12.72
+0.04
(+0.35%)
USD |
NASDAQ |
Sep 08, 16:00
12.73
0.00 (0.00%)
Pre-Market: 20:00
Benitec Biopharma Total Liabilities (Quarterly) : 3.668M for March 31, 2026
Total Liabilities (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2026 | 3.668M |
| December 31, 2025 | 3.32M |
| September 30, 2025 | 2.428M |
| June 30, 2025 | 2.297M |
| March 31, 2025 | 7.639M |
| December 31, 2024 | 3.127M |
| September 30, 2024 | 4.594M |
| June 30, 2024 | 4.962M |
| March 31, 2024 | 3.499M |
| December 31, 2023 | 5.883M |
| September 30, 2023 | 4.745M |
| June 30, 2023 | 4.262M |
| March 31, 2023 | 3.507M |
| December 31, 2022 | 2.911M |
| September 30, 2022 | 3.502M |
| June 30, 2022 | 3.091M |
| March 31, 2022 | 2.544M |
| December 31, 2021 | 3.178M |
| September 30, 2021 | 2.361M |
| June 30, 2021 | 1.369M |
| March 31, 2021 | 2.498M |
| Date | Value |
|---|---|
| December 31, 2020 | 0.887M |
| September 30, 2020 | 1.18M |
| June 30, 2020 | |
| March 31, 2020 | 1.244M |
| December 31, 2019 | |
| September 30, 2019 | |
| June 30, 2019 | 2.641M |
| March 31, 2019 | |
| December 31, 2018 | |
| September 30, 2018 | |
| June 30, 2018 | |
| March 31, 2018 | |
| December 31, 2017 | |
| September 30, 2017 | |
| June 30, 2017 | |
| March 31, 2017 | |
| December 31, 2016 | |
| September 30, 2016 | 0.7346M |
| June 30, 2016 | |
| March 31, 2016 | 1.714M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Liabilities (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 436.29M |
| Alnylam Pharmaceuticals, Inc. | 4.205B |
| Anika Therapeutics, Inc. | 46.19M |
| Savara, Inc. | 48.48M |
| Vericel Corp. | 132.82M |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 187.00M |
| Shareholders Equity (Quarterly) | 183.33M |
| Debt to Equity Ratio | 0.0048 |
| Current Ratio | 56.82 |
| Net Debt Paydown Yield | -0.04% |